FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980976770> ?p ?o ?g. }

• W2980976770 endingPage "5333" @default.
• W2980976770 startingPage "5333" @default.
• W2980976770 abstract "Abstract Introduction: Indolent B-cell lymphoma is a type of non-Hodgkin's lymphoma that grows slowly and is not a curative disease. Yttrium-90 (90Y) iburitumomab tiuxetan is used in patients with relapsed/refractory indolent B-cell lymphoma, data is still limited in the rituximab era. In addition, previous studies did not assess the impact of early progression of disease within 2 years (POD24) which was reported to be associated with a poor prognosis in follicular lymphoma (Casulo et al, J Clin Oncol 2015) on the efficacy of 90Y iburitumomab tiuxetan. Thus, here we assessed the efficacy of 90Y iburitumomab tiuxetan in relapsed/refractory indolent B-cell lymphoma, and analyzed the impact of POD24 in this setting. Methods: We retrospectively analyzed the clinical outcomes of 51 patients with a relapsed/refractory indolent B-cell lymphoma who received 90Y iburitumomab tiuxetan at our institute from February 2009 to January 2018. POD24 was defined as progression within 24 months from the beginning of induction chemotherapy. Survival outcomes including overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Results: The median age was 64 years (range 37-88 years) at the time of receiving 90Y iburitumomab tiuxetan, and 29 (56.9%) were male. Disease subtypes were as follows: follicular lymphoma (n=44, 86.3%), mantle cell (n=4, 7.8%), marginal zone (n=2, 3.9%), and MALT lymphoma (n=1, 2.0%). The median number of previous regimens was 2 (range 1-9) and included rituximab-based therapy in all patients. Disease status at the time of receiving 90Y iburitumomab tiuxetan were as follows: complete remission (CR n=3, 5.9%), partial remission (PR n=13, 25.5%), stable disease (SD n=3, 5.9%), progression disease (PD n=32, 62.7%). The median follow-up time was 3.7 years (range 0.3-8.8 years) and overall response rate (ORR) was 94.1% (CR 56.9%, PR 37.3%). The ORR in patients with POD 24 was 95.0% (CR 60.0%, PR 35.0%), compared to 93.5% (CR 54.8%, PR 38.7%) with non-POD24. The 3-year OS and PFS rates for all patients receiving 90Y iburitumomab tiuxetan were 83.6% and 41.0%, respectively. POD24 was a significant prognostic factor for PFS in univariate analysis (1.2 years in patients with POD24 vs. 3.3 years in patients with non-POD24, (P=0.02) (Figure1). In multivariate analysis, POD24 was an independent prognostic marker of PFS (hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.22-0.87, P=0.02). Conclusion: 90Y iburitumomab tiuxetan was highly effective in patients with relapsed/refractory indolent B-cell lymphoma patients. However, in patients with POD24, duration of response was short. Thus, another treatment strategy including hematopoietic stem cell transplantation should be considered. Disclosures No relevant conflicts of interest to declare." @default.
• W2980976770 created "2019-10-25" @default.
• W2980976770 creator A5000487600 @default.
• W2980976770 creator A5016157097 @default.
• W2980976770 creator A5022150740 @default.
• W2980976770 creator A5030123886 @default.
• W2980976770 creator A5038924268 @default.
• W2980976770 creator A5045183998 @default.
• W2980976770 creator A5048030394 @default.
• W2980976770 creator A5065025175 @default.
• W2980976770 creator A5080908654 @default.
• W2980976770 creator A5088319282 @default.
• W2980976770 date "2018-11-29" @default.
• W2980976770 modified "2023-10-16" @default.
• W2980976770 title "Efficacy of Yttrium-90 Iburitumomab Tiuxetan for Early Relapsed/Refractory Indolent B-Cell Lymphoma: A Single Institute Retrospective Analysis in the Rituximab Era" @default.
• W2980976770 doi "https://doi.org/10.1182/blood-2018-99-112782" @default.
• W2980976770 hasPublicationYear "2018" @default.
• W2980976770 type Work @default.
• W2980976770 sameAs 2980976770 @default.
• W2980976770 citedByCount "0" @default.
• W2980976770 crossrefType "journal-article" @default.
• W2980976770 hasAuthorship W2980976770A5000487600 @default.
• W2980976770 hasAuthorship W2980976770A5016157097 @default.
• W2980976770 hasAuthorship W2980976770A5022150740 @default.
• W2980976770 hasAuthorship W2980976770A5030123886 @default.
• W2980976770 hasAuthorship W2980976770A5038924268 @default.
• W2980976770 hasAuthorship W2980976770A5045183998 @default.
• W2980976770 hasAuthorship W2980976770A5048030394 @default.
• W2980976770 hasAuthorship W2980976770A5065025175 @default.
• W2980976770 hasAuthorship W2980976770A5080908654 @default.
• W2980976770 hasAuthorship W2980976770A5088319282 @default.
• W2980976770 hasConcept C121332964 @default.
• W2980976770 hasConcept C126322002 @default.
• W2980976770 hasConcept C142424586 @default.
• W2980976770 hasConcept C143998085 @default.
• W2980976770 hasConcept C159654299 @default.
• W2980976770 hasConcept C203014093 @default.
• W2980976770 hasConcept C207103383 @default.
• W2980976770 hasConcept C2776146153 @default.
• W2980976770 hasConcept C2776694085 @default.
• W2980976770 hasConcept C2777058707 @default.
• W2980976770 hasConcept C2777525834 @default.
• W2980976770 hasConcept C2778453870 @default.
• W2980976770 hasConcept C2778515704 @default.
• W2980976770 hasConcept C2778563104 @default.
• W2980976770 hasConcept C2779338263 @default.
• W2980976770 hasConcept C2779921676 @default.
• W2980976770 hasConcept C2780653079 @default.
• W2980976770 hasConcept C2780739268 @default.
• W2980976770 hasConcept C44249647 @default.
• W2980976770 hasConcept C542903549 @default.
• W2980976770 hasConcept C71924100 @default.
• W2980976770 hasConcept C87355193 @default.
• W2980976770 hasConcept C90924648 @default.
• W2980976770 hasConceptScore W2980976770C121332964 @default.
• W2980976770 hasConceptScore W2980976770C126322002 @default.
• W2980976770 hasConceptScore W2980976770C142424586 @default.
• W2980976770 hasConceptScore W2980976770C143998085 @default.
• W2980976770 hasConceptScore W2980976770C159654299 @default.
• W2980976770 hasConceptScore W2980976770C203014093 @default.
• W2980976770 hasConceptScore W2980976770C207103383 @default.
• W2980976770 hasConceptScore W2980976770C2776146153 @default.
• W2980976770 hasConceptScore W2980976770C2776694085 @default.
• W2980976770 hasConceptScore W2980976770C2777058707 @default.
• W2980976770 hasConceptScore W2980976770C2777525834 @default.
• W2980976770 hasConceptScore W2980976770C2778453870 @default.
• W2980976770 hasConceptScore W2980976770C2778515704 @default.
• W2980976770 hasConceptScore W2980976770C2778563104 @default.
• W2980976770 hasConceptScore W2980976770C2779338263 @default.
• W2980976770 hasConceptScore W2980976770C2779921676 @default.
• W2980976770 hasConceptScore W2980976770C2780653079 @default.
• W2980976770 hasConceptScore W2980976770C2780739268 @default.
• W2980976770 hasConceptScore W2980976770C44249647 @default.
• W2980976770 hasConceptScore W2980976770C542903549 @default.
• W2980976770 hasConceptScore W2980976770C71924100 @default.
• W2980976770 hasConceptScore W2980976770C87355193 @default.
• W2980976770 hasConceptScore W2980976770C90924648 @default.
• W2980976770 hasIssue "Supplement 1" @default.
• W2980976770 hasLocation W29809767701 @default.
• W2980976770 hasOpenAccess W2980976770 @default.
• W2980976770 hasPrimaryLocation W29809767701 @default.
• W2980976770 hasRelatedWork W1518799304 @default.
• W2980976770 hasRelatedWork W1999257868 @default.
• W2980976770 hasRelatedWork W2032191337 @default.
• W2980976770 hasRelatedWork W2033236745 @default.
• W2980976770 hasRelatedWork W2148853365 @default.
• W2980976770 hasRelatedWork W2171378384 @default.
• W2980976770 hasRelatedWork W2281407427 @default.
• W2980976770 hasRelatedWork W2413612383 @default.
• W2980976770 hasRelatedWork W2980976770 @default.
• W2980976770 hasRelatedWork W3040245446 @default.
• W2980976770 hasVolume "132" @default.
• W2980976770 isParatext "false" @default.
• W2980976770 isRetracted "false" @default.
• W2980976770 magId "2980976770" @default.
• W2980976770 workType "article" @default.